Facebook icon Twitter icon Forward icon

NICE propose more weight loss surgery to tackle Type 2 diabetes

The National Institute of Health and Care Excellence (NICE) is proposing more weight loss surgery in England to tackle Type 2 diabetes.

The health watchdog is proposing to lower the threshold for bariatric surgery for people with newly-diagnosed Type 2 diabetes to a BMI of 30. Until now, it has said that people with Type 2 diabetes could be considered for a gastric band at a BMI of 35.

The move could see an extra 850,000 people eligible for surgery, according to Diabetes UK. Being overweight is a risk factor in the development of Type 2 diabetes.

To read more, click here.

Living with Diabetes Survey

A diabetes charity is urging people with the condition to complete a food-themed survey to help inform future campaigning work.

The InDependent Diabetes Trust has launched its Living with Diabetes Survey 2014, with the short questionnaire covering food and diet as well as other key aspects.

It comes on the back of the trust’s recently launched and successful book Diabetes – Food, Meds and More.

To read more, click here.

Back to Basics – Ninjabetic

The 15 healthcare essentials… a check list for all patients with diabetes (devised by Diabetes UK) to show them what they should expect, in terms of basic care, from the HCPs (health care professionals) they see.

How many of these do patients get? Obviously not everyone will need all 15 (which makes fitting them in a little easier), but how many of us patients get everything we need once a year? Personally, I need 12 of the 15 and in the last year I’ve had 6.5 of these (I gave 1/2 a point as I get emotional support, but it’s not psychological), from my diabetes specialist team.

To read more, click here.

Novo Nordisk's Insulin Degludec/Liraglutide set to become gold standard

Novo Nordisk's degludec/liraglutide (Xultophy, formerly known as IDegLira) is set to become the clinical gold standard among fixed-dose combination (FDC) therapy insulin used to treat people with Type 2 diabetes, according to a leading health analysis group.

The competitive advantages that this long-acting insulin analogue/glucagon-like peptide (GLP)-1 receptor agonist FDC has over other FDCs are due to the combined actions of the highly efficacious individual components on various measures of glycaemic control, according to a new report from Decision Resources Group.

To read more, click here.